Diuretics and advanced features of nephroprotection

Authors

  • D.D. Ivanov Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine http://orcid.org/0000-0003-2609-0051
  • Lionel Rostaing Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France

DOI:

https://doi.org/10.22141/2307-1257.8.1.2019.157790

Keywords:

diuretics, chronic kidney disease, loop diuretics, sodium-glucose co-transporter 2 inhibitor, nephroprotection

Abstract

The most frequently used diuretics in nephrology, and the scheme and dosages used for their prescription are considered. Attention is focused on a new class of hypoglycemic drugs (gliflozins) that can provide nephroprotection to patients with diabetic nephropathy, and probably those with chronic kidney disease without diabetes mellitus type 2.

Downloads

Download data is not yet available.

References

Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Jan 1. doi: 10.1002/ejhf.1369.

Clark WF, Sontrop JM, Huang SH, et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial. JAMA. 2018 May 8;319(18):1870-1879. doi: 10.1001/jama.2018.4930.

Ivanov DD, Gozhenko AI, Savitskay LN. Renoprotection and its association with eGFR and renal functional reserve. Pocki. 2018;7(4):238-244. doi: 10.22141/2307-1257.7.4.2018.148512.

Cosin J, Díez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002 Aug;4(4):507-13.

The TORAFIC Investigators Group. Effects of Prolonged-Release Torasemide Versus Furosemide on Myocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded-End Point, Active-Controlled Study. Clin Ther. 2011 Sep;33(9):1204-1213.e3. doi: 10.1016/j.clinthera.2011.08.006.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033.

Ottosson-Laakso E, Tuomi T, Forsén B, et al. Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time. PLoS One. 2016 Jan 6;11(1):e0146114. doi: 10.1371/journal.pone.0146114.

DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x.

Ivanov DD. RAS antagonists correct hyperfiltration in DKD stage 1. Nephrology Dialysis Transplantation. 2018 May;33(Suppl 1):i493. doi: 10.1093/ndt/gfy104.SP429.

Ivanov DD, Sinjchenko OV, Golovach IYu, Bevzenko TB, Ivanova MD. THU0687 The impact of urate-lowering therapy on kidney function (IMPULSKF): preliminary results. Annals of the Rheumatic Diseases 2018;77(Suppl 2):537. doi: 10.1136/annrheumdis-2018-eular.3962.

Ivanov D, Ivanova М, Bevzenko T. Febuxostat improves GFR and BP in non-diabetic adults with CKD 2-3: 6 years treatment and follow-up. Nephrology Dialysis Transplantation2018 May;33(suppl 1):i626. doi: 10.1093/ndt/gfy104.SuO025.

Downloads

Published

2021-09-08

How to Cite

Ivanov, D., & Rostaing, L. (2021). Diuretics and advanced features of nephroprotection. KIDNEYS, 8(1), 2–6. https://doi.org/10.22141/2307-1257.8.1.2019.157790

Issue

Vol. 8 No. 1 (2019)

Section

Cover story

License

Copyright (c) 2019 D.D. Ivanov, Lionel Rostaing

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>